Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040829 | 0.88 | LTA4H (0.66) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2987817 | 0.87 | RAB9A (0.74) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4339818 | 0.87 | SIRT2 (0.53) | LTA4HKMT2A | |
| SCHEMBL7722182 | 0.85 | CYP17A1 (0.53) | RAB9ANPC1KMT2A | |
| SCHEMBL15201328 | 0.85 | RAB9A (0.60) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6635582 | 0.85 | NPFFR1 (0.52) | RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL4068749 | 0.83 | LTA4H (0.72) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL8693590 | 0.83 | CA1 (0.54) | RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL2009888 | 0.83 | HDAC1 (0.55) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL31509543 | 0.83 | RAB9A (0.49) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104220058-A | Serine racemase inhibitor | NAT UNIV CORP UNIV TOYAMA | 2014-12-17 | — | — | CN | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | LTA4H 951/4885RAB9A 2258/4885SMN1; SMN2 3084/4885 |
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | LTA4H 759/4885RAB9A 2314/4885SMN1; SMN2 1321/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | LTA4H 759/4885RAB9A 2314/4885SMN1; SMN2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.